Guillain-Barré syndrome following meningococcal meningitis.

Risk of Guillain-Barré syndrome following serogroup C meningococcal conjugate vaccine in Quebec, Canada.

To assess the risk of Guillain-Barré syndrome (GBS) following administration of meningococcal serogroup C-CRM(197) conjugate vaccine, provincial immunization records were linked with hospital discharge records, and medical charts were reviewed. In the cohort of 1.9 million individuals (age, 2 months to 20 years), observed postvaccination frequencies of GBS were not higher than expected.

Detection of Autoantibodies against Gangliosides in Guillain-Barré Syndrome

Epidemiology of Guillain-Barré syndrome in the province of Quebec.

BACKGROUND In the province of Quebec, a population-based study of Guillain-Barré syndrome (GBS) was conducted at the time of a mass immunization campaign against meningococcal disease, in 2001. METHODS The study population included residents aged 2 months to 20 years observed from November 1st, 2000 to December 31, 2002, representing 4,075,465 person-years of observation. GBS cases were ident...

Guillain-Barré syndrome following acute head trauma.

A case of classical Guillain-Barré syndrome following acute head trauma is described. The association of Guillain-Barré syndrome with head injury per se is not well recognized, and a possible immunological explanation is proposed.

Acute aseptic meningitis due to intravenous immunoglobulin therapy in Guillain–Barré syndrome

The majority of adverse reactions of intravenous immunoglobulin (IVIG) therapy are mild, transient and self-limiting with potentially serious complications occurring in <5% of patients. IVIG-associated transient aseptic meningitis is one such rare adverse effect, which has been seldomly described in the literature. We report a case of aseptic meningitis due to IVIG therapy in a Guillain-Barré s...